

File Copy

WEST[Help](#) [Logout](#) [Interrupt](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#) [Preferences](#)**Search Results -**

Terms	Documents
L7 and (N-terminal and fibrin binding domain)	264

Database:

Search History**Today's Date: 12/31/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	L7 and (N-terminal and fibrin binding domain)	264	<u>L10</u>
USPT	L6 and (N-terminal and fibrin binding domain)	458	<u>L9</u>
USPT	L6 and fibrin containing substance	1124798	<u>L8</u>
USPT	L6 and (thrombus or atherosclerotic plaque)	272	<u>L7</u>
USPT	L4 and fibrin	498	<u>L6</u>
USPT	L4 and (L1 or fibrin)	2193	<u>L5</u>
USPT	L1 and (marker or image or isotope or label)	2193	<u>L4</u>
USPT	L2 not L1	174782	<u>L3</u>
USPT	fibrin binding domain\$	178109	<u>L2</u>
USPT	fibronectin\$	3975	<u>L1</u>

=> d his

File Copy

(FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000)

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT
18:07:49 ON 31 DEC 2000

L1 96041 S FIBRONECTIN
L2 31 S L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)
L3 3979 S L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)
L4 2707 S L1 AND FIBRIN
L5 31 S L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)
L6 118 S L4 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)
L7 2 S L5 AND L6

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT
18:26:10 ON 31 DEC 2000

L8 96041 S FIBRONECTIN
L9 84300 S FIBRIN
L10 17 S L9 AND (N-TERMINAL FIBRIN BINDING DOMAIN)
L11 1917 S L9 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)
L12 927 DUP REM L11 (990 DUPLICATES REMOVED)
L13 116 S L12 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)
L14 0 S L12 AND (N-TERMINAL FIBRIN BINDING DOMAIN)
L15 0 S L10 AND L13
L16 0 S L2 AND L12
L17 0 S L2 AND L13

STN

Search Strategy

File Copy

09-047, 661 8/11/00

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1600RXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent Files
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPII
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files
NEWS 10 Dec 15 2001 STN Pricing
NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and biotechnology
NEWS 12 Dec 17 Corrosion Abstracts on STN
NEWS 13 Dec 17 SYNTHLINE from Prous Science now available on STN
NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files

NEWS EXPRESS FREE UPGRADE 5.0DP1 FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

- *CFR - Code of Federal Regulations 1997 - present
- *CHEMCATS - CHEMICAL CATALOGS ONLINE 1993-1997

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000

=> File biosis, embase, medline, scisearch, lifesci, caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'BIOSIS' ENTERED AT 18:07:49 ON 31 DEC 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 18:07:49 ON 31 DEC 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 18:07:49 ON 31 DEC 2000

FILE 'SCISEARCH' ENTERED AT 18:07:49 ON 31 DEC 2000

COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 18:07:49 ON 31 DEC 2000

COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 18:07:49 ON 31 DEC 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fibronectin

=> s fibronectin

L1 96041 FIBRONECTIN

=> s L1 and (N-terminal and fibrin binding domain)

L2 31 L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

=> s L1 and (marker or image or isotope or label)

L3 3979 L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

=> s L1 and fibrin

L4 2707 L1 AND FIBRIN

=> s L4 and (N-terminal and fibrin binding domain)

L5 31 L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

=> s L4 and (thrombus or atherosclerotic plaque)

L6 118 L4 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)

=> s L5 and L6

L7 2 L5 AND L6

=> d his

(FILE 'HOME' ENTERED AT 18:06:32 ON 31 DEC 2000)

FILE 'BIOSIS, EMBASE, MEDLINE, SCISEARCH, LIFESCI, CAPLUS' ENTERED AT
18:07:49 ON 31 DEC 2000

L1 96041 S FIBRONECTIN

L2 31 S L1 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)

L3 3979 S L1 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

L4 2707 S L1 AND FIBRIN
L5 31 S L4 AND (N-TERMINAL AND FIBRIN BINDING DOMAIN)
L6 118 S L4 AND(THROMBUS OR ATHEROSCLEROTIC PLAQUE)
L7 2 S L5 AND L6

=> d L7 1-2 bib kwic

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1997:277041 CAPLUS
DN 127:31973
TI Recombinant polypeptides derived from the **fibrin binding domain of fibronectin** are potential agents for the imaging of blood clots
AU Ezov, N.; Nimrod, A.; Parizada, B.; Werber, M. M.; Goldlust, A.; Greenstein, L. A.; Vogel, T.; Drizlich, N.; Levanon, A.; Reich, S.; Gorecki, M.; Panet, Amos
CS Bio-Technology General, Rehovot, 76326, Israel
SO Thromb. Haemostasis (1997), 77(4), 796-803
CODEN: THHADQ; ISSN: 0340-6245
PB Schattauer
DT Journal
LA English
TI Recombinant polypeptides derived from the **fibrin binding domain of fibronectin** are potential agents for the imaging of blood clots
AB **Thrombus** formation in the circulation is accompanied by covalent linkage of **fibronectin** (FN) through transglutamination of GLN-3 in the **fibrin binding N-terminal** domain (FBD) of FN. This phenomenon was exploited for **thrombus** detection by the employment of radioactively-labeled recombinant polypeptide mols. derived from the 5-finger FBD of human FN. Three recombinant FBD polypeptides, 12 kDa ("2 fingers"), 18.5 kDa ("3 fingers"), and 31 kDa FBD ("5 fingers"), were prep'd. and compared to native FN-derived 31 kDa-FBD with respect to their ability to attach to **fibrin** clots in vitro and in vivo. The accessibility of Gln-3 in these mols. was demonstrated by the incorporation of stoichiometric amts. of ¹⁴C-putrescine in the presence of plasma transglutaminase. Competitive binding expts. to **fibrin** have indicated that, although the binding affinities of the FBD mols. are lower than that of FN, substantial covalent linkage was obtained in the presence of transglutaminase, and in the presence of excess FN or heparin. The biol. clearance rates of labeled FBD mols. in rats and rabbits were much higher than those of FN and fibrinogen. The 12 kDa FBD exhibited the highest rate of clearance. The potential of the 12 kDa and 31 kDa FBDs as imaging agents was examd. in a stainless steel coil-induced **thrombus** model in rats and in a jugular vein **thrombus** model in rabbits. At 24 h, clot-to-blood ratios ranged between 10-22 for [¹²⁵I]-12 kDa FBD and 40-60 for [¹¹¹In]-12 kDa FBD. In the rat model, heparin did not inhibit the uptake of FBD.
ST **fibronectin fibrin fibrinogen thrombus**
IT Fibrins
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(competitive inhibition of biotinylated r12 kDa **fibrin binding domain** binding to **fibrin**)
IT Thrombus
(**fibrin binding N-terminal** domain of **fibronectin** for **thrombus** detection)
IT Proteins (specific proteins and subclasses)
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(**fibronectin**-binding, 12 kDa, 18.5 kDa, 31 kDa polypeptides;

fibrin binding N-terminal domain of
 fibronectin for thrombus detection)

IT Fibronectins
 RL: BAC (Biological activity or effector, except adverse); BOC
 (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (role of thrombus formation)

IT 80146-85-6, Transglutaminase
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (competitive inhibition of biotinylated r12 kDa **fibrin**
 binding domain binding to **fibrin**)

IT 9005-49-6, Heparin, biological studies
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (effect of heparin on the binding of 12 kDa **fibrin** binding
 N-terminal domain of **fibronectin** to blood
 clots)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS
 AN 1991:137413 CAPLUS
 DN 114:137413
 TI Cloning of gene for human **fibronectin** analogs, its recombinant
 manufacture, and pharmaceuticals contg. same
 IN Vogel, Tikva; Levanon, Avigdor; Werber, Moshe; Guy, Rachel; Panet, Amos
 PA Bio-Technology General Corp., USA
 SO PCT Int. Appl., 295 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9007577	A1	19900712	WO 1989-US5875	19891229
	W: AU, DK, FI, JP, KR, NL RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE				
	CA 2006929	AA	19900629	CA 1989-2006929	19891229
	AU 9049598	A1	19900801	AU 1990-49598	19891229
	AU 636596	B2	19930506		
	EP 451211	A1	19911016	EP 1990-902086	19891229
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04505698	T2	19921008	JP 1990-502804	19891229
	JP 3095771	B2	20001010		
	DK 9101280	A	19910829	DK 1991-1280	19910628
	US 5455158	A	19951003	US 1993-58241	19930504
	US 5679320	A	19971021	US 1994-259569	19940614
	US 5965383	A	19991012	US 1995-409750	19950324
	US 5869616	A	19990209	US 1997-826885	19970408
	US 6121426	A	20000919	US 1997-909140	19970811
PRAI	US 1988-291951	19881229			
	US 1989-345952	19890428			
	CA 1989-2006929	19891229			
	WO 1989-US5875	19891229			
	US 1990-526397	19900521			
	US 1991-703842	19910521			
	US 1993-58241	19930504			
	US 1994-259569	19940614			
	US 1995-409750	19950324			
TI	Cloning of gene for human fibronectin analogs, its recombinant manufacture, and pharmaceuticals contg. same				
AB	Fibronectin fragments contg. the cell-binding domain or the fibrin-binding domain for use inter alia as platelet-aggregation inhibitors, in wound healing and in the prevention of				
	iatrogenic infections are manufd. by expression of a cDNA encoding the domain in Escherichia coli. These fragments are not necessarily the same as those derived by proteolysis of fibronectin . A				

fibronectin cDNA was cloned from a human liver cDNA bank in *.lambda.gt11* using oligonucleotides probes for regions of the N-terminal and cell-binding domains. After recovery of the complete sequence the regions encoding individual domains were subcloned and expressed in *E. coli*. In platelet aggregation inhibition assays a 40 kilodalton cell-binding domain inhibited aggregation 40% at 0.5 μ M.

- In the same assay the pentapeptide GRGDS was as effective at 25 μ M. The 31 kilodalton **fibrin-binding domain** was shown to bind to *Staphylococcus aureus* as effectively as the comparable proteolytic fragment.
- ST **fibronectin** cDNA cloning expression *Escherichia*; platelet aggregation inhibitor recombinant **fibronectin**; wound healing recombinant **fibronectin** fragment; bacterial colonization inhibitor recombinant **fibronectin**; catheter coating recombinant **fibronectin** fragment
- IT Gene and Genetic element, animal
RL: BIOL (Biological study)
(cDNA, for **fibronectin** of cell- and **fibrin**-binding domains, of human, cloning and expression in *Escherichia coli* of,)
- IT Fibronectins
RL: BIOL (Biological study)
(cell- and **fibrin**-binding domains of, for therapeutic uses, recombinant manuf. of, cloning of **fibronectin** cDNA in *Escherichia coli* in relation to)
- IT *Escherichia coli*
(cloning and expression in, of **fibronectin** cell- and **fibrin-binding domain** cDNAs, of human)
- IT Blood-coagulation factors
Interferons
RL: BIOL (Biological study)
(conjugates with **fibronectin** domain peptides, pharmaceutical uses of)
- IT Neoplasm
Thrombus and Blood clot
(detection of, **fibronectin** domains for, recombinant manuf. of)
- IT Wound healing
(**fibronectin** derivs. for treatment of, recombinant manuf. of)
- IT Fibrins
RL: BIOL (Biological study)
(**fibronectin** domain binding, analogs of, recombinant manuf. of)
- IT Fermentation
(**fibronectin** domain-contg. polypeptides, with recombinant *Escherichia coli*)
- IT Blood platelet aggregation inhibitors
(**fibronectin** domains as, recombinant manuf. of)
- IT Bacteria
Staphylococcus aureus
(**fibronectin** domains binding to, 31,000 mol.-wt., recombinant manuf. of)
- IT Thrombolytics
(**fibronectin** domains conjugated fibrinolytic enzymes as)
- IT Extracellular matrix
(**fibronectin** **fibrin-binding domain** binding to)
- IT Burn
(healing of, stimulation of, **fibronectin** domains for, recombinant manuf. of)
- IT Molecular cloning
(of **fibronectin** cDNA, of human, in *Escherichia coli*)
- IT Drug bioavailability
(of **fibronectin** domain peptides, of human, in rats)
- IT Thromboxanes
RL: BIOL (Biological study)

(release from platelets of, inhibition of, **fibronectin**
 derivs. for)

IT Eye, disease or disorder
Tendon
 (wounding of, healing of, stimulation of, **fibronectin** domains
 for, recombinant manuf. of)

IT Heart, disease or disorder
 (angina pectoris, **fibronectin** derivs. for treatment of,
 recombinant manuf. of)

IT Artery, disease or disorder
 (angioplasty, recovery from, platelet aggregation inhibition in,
 fibronectin domains and conjugates for)

IT Animal growth regulators
RL: BIOL (Biological study)
 (blood platelet-derived growth factors, conjugates with
 fibronectin domain peptides, pharmaceutical uses of)

IT Medical goods
 (catheters, as route for infection, **fibronectin** domains as
 coating for prevention of)

IT Brain, disease or disorder
 (cerebrovascular, treatment of, use of **fibronectin** domains as
 platelet-aggregation inhibitors in)

IT Albumins, compounds
RL: BIOL (Biological study)
 (conjugates, with **fibronectin** domain peptides, pharmaceutical
 uses of)

IT Eye, disease or disorder
 (cornea, epithelium, wounding of, healing of, stimulation of,
 fibronectin domains for, recombinant manuf. of)

IT Eye, disease or disorder
 (cornea, stroma, wounding of, healing of, stimulation of,
 fibronectin domains for, recombinant manuf. of)

IT Cardiovascular system
 (disease, **fibronectin** derivs. for treatment of, recombinant
 manuf. of)

IT Circulation
 (extracorporeal, cardiopulmonary bypass, recovery from, platelet
 aggregation inhibition in, **fibronectin** domains and conjugates
 for)

IT Animal growth regulators
RL: BIOL (Biological study)
 (fibroblast-derived growth factors, conjugates with **fibronectin**
 domain peptides, pharmaceutical uses of)

IT Deoxyribonucleic acid sequences
 (**fibronectin**-specifying, of human, complete)

IT Heart, disease or disorder
 (infarction, acute, **fibronectin** derivs. for treatment of,
 recombinant manuf. of)

IT Lymphokines and Cytokines
RL: BIOL (Biological study)
 (interleukins, conjugates with **fibronectin** domain peptides,
 pharmaceutical uses of)

IT Plasmid and Episome
 (pFN126-3, gene for human **fibronectin** domain on, expression
 in *Escherichia coli* of)

IT Plasmid and Episome
 (pFN132-5, gene for human **fibronectin** domain on, expression
 in *Escherichia coli* of)

IT Plasmid and Episome
 (pFN137-2, gene for human **fibronectin** domain on, expression
 in *Escherichia coli* of)

IT Plasmid and Episome
 (pFN949-2, gene for human **fibronectin** domain on, expression
 in *Escherichia coli* of)

IT Plasmid and Episome
 (pFN975-25, gene for human **fibronectin** domain on, expression

in Escherichia coli of)
 IT Skin, disease or disorder
 (transplant, healing of, stimulation of, **fibronectin** domains
 for, recombinant manuf. of)
 IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (tumor necrosis factor, conjugates with **fibronectin** domain
 peptides, pharmaceutical uses of)
 IT Animal growth regulators
 RL: BIOL (Biological study)
 (.alpha.-transforming growth factors, conjugates with
fibronectin domain peptides, pharmaceutical uses of)
 IT Animal growth regulators
 RL: BIOL (Biological study)
 (.beta.-transforming growth factors, conjugates with
fibronectin domain peptides, pharmaceutical uses of)
 IT 9002-01-1D, Streptokinase, conjugates with **fibronectin** domain
 peptides 9039-53-6D, Urokinase, conjugates with **fibronectin**
 domain peptides 81669-57-0D, Eminase, conjugates with
fibronectin domain peptides 82657-92-9D, Prourokinase,
 conjugates with **fibronectin** domain peptides
 RL: PRP (Properties)
 (as thrombolytic)
 IT 80146-85-6, Transglutaminase
 RL: PRP (Properties)
 (binding of **fibronectin** domain polypeptides to **fibrin**
 stimulation by)
 IT 9001-27-8D, Blood-coagulation factor VIII, conjugates with
fibronectin domain peptides 9013-56-3D, Blood-coagulation factor
 XIII, conjugates with **fibronectin** domain peptides 9054-89-1D,
 Superoxide dismutase, conjugates with **fibronectin** domain
 peptides 11096-26-7D, Erythropoietin, conjugates with
fibronectin domain peptides 25322-68-3D, conjugates with
fibronectin domain peptides 62229-50-9D, Epidermal growth
 factor, conjugates with **fibronectin** domain peptides
 62683-29-8D, Colony-stimulating factor, conjugates with
fibronectin domain peptides 81627-83-0D, Colony-stimulating
 factor 1, conjugates with **fibronectin** domain peptides
 83869-56-1D, Colony-stimulating factor 2, conjugates with
fibronectin domain peptides
 RL: PRP (Properties)
 (pharmaceutical uses of)
 IT 57576-52-0, Thromboxane A2
 RL: PRP (Properties)
 (release from platelets of, inhibition of, **fibronectin**
 derivs. for)
 IT 105913-11-9D, Plasminogen activator, conjugates with **fibronectin**
 domain peptides
 RL: PRP (Properties)
 (tissue-type, as thrombolytic)

=> File biosis, embase, medline, scisearch, lifesci, caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.95	56.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.18	-1.18

FILE 'BIOSIS' ENTERED AT 18:26:10 ON 31 DEC 2000
 COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 18:26:10 ON 31 DEC 2000

FILE 'SCISEARCH' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 18:26:10 ON 31 DEC 2000

COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 18:26:10 ON 31 DEC 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fibronectin

L8 96041 FIBRONECTIN

=> s fibrin

L9 84300 FIBRIN

=> s L9 and (N-terminal fibrin binding domain)

L10 17 L9 AND (N-TERMINAL FIBRIN BINDING DOMAIN)

=> s L9 and (marker or image or isotope or label)

L11 1917 L9 AND (MARKER OR IMAGE OR ISOTOPE OR LABEL)

=> dup rem L11

PROCESSING IS APPROXIMATELY 46% COMPLETE FOR L11

PROCESSING IS APPROXIMATELY 84% COMPLETE FOR L11

PROCESSING COMPLETED FOR L11

L12 927 DUP REM L11 (990 DUPLICATES REMOVED)

=> L12 and (thrombus or atherosclerotic plaque)

L12 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (>).

=> s L12 and (thrombus or atherosclerotic plaque)

L13 116 L12 AND (THROMBUS OR ATHEROSCLEROTIC PLAQUE)

=> s L12 and (N-terminal fibrin binding domain)

L14 0 L12 AND (N-TERMINAL FIBRIN BINDING DOMAIN)

=> s L10 and L13

L15 0 L10 AND L13

=> s L2 and L12

L16 0 L2 AND L12

=> s L2 and L13

L17 0 L2 AND L13